The human thrombopoietin gene is located on chromosome 3q26.33-q27, but is not transcriptionally activated in leukemia cells with 3q21 and 3q26 abnormalities (3q21q26 syndrome).

Abstract:

:We previously demonstrated that the EVI-1 gene was transcriptionally activated in the 3q21q26 syndrome and chromosomal breakpoints at 3q26 were clustered within 400 Kb of the EVI-1 gene. Since thrombocytosis is often observed in the 3q21q26 syndrome, we first mapped the thrombopoietin (TPO) gene and then we examined for transcriptional activation and chromosomal rearrangement of the TPO gene in four cases of the 3q21q26 syndrome. The TPO gene was assigned to chromosome 3q26.33-q27 by fluorescence in situ hybridization analysis. Although the TPO gene was mapped to the same locus as the EVI-1 gene, the distance between the TPO gene and the EVI-1 gene at 3q26 was more than 600 Kb and no gross chromosomal rearrangements of the TPO gene were detected by Southern blot analysis and pulsed field gel electrophoresis (PFGE) analysis. TPO transcripts were not detected in these leukemia cells by Northern blot analysis. These results indicate that activation of the TPO gene is not the main cause of thrombocytosis in the 3q21q26 syndrome.

journal_name

Leukemia

journal_title

Leukemia

authors

Suzukawa K,Satoh H,Taniwaki M,Yokota J,Morishita K

subject

Has Abstract

pub_date

1995-08-01 00:00:00

pages

1328-31

issue

8

eissn

0887-6924

issn

1476-5551

journal_volume

9

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia.

    abstract::To assess the efficacy and toxicity of HAA regimen (homoharritonine 4 mg/m2/day, days 1-3; cytarabine 150 mg/m2/day, days 1-7; aclarubicin 12 mg/m2/day, days 1-7) as an induction therapy in the treatment of de novo acute myeloid leukemia (AML), 48 patients with newly diagnosed AML, aged 35 (14-57) years, were entered ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404287

    authors: Jin J,Jiang DZ,Mai WY,Meng HT,Qian WB,Tong HY,Huang J,Mao LP,Tong Y,Wang L,Chen ZM,Xu WL

    更新日期:2006-08-01 00:00:00

  • Frequent detection of minimal residual disease by use of the polymerase chain reaction in long-term survivors after bone marrow transplantation for chronic myeloid leukemia.

    abstract::The polymerase chain reaction (PCR) allows the detection of minimal amounts of nucleic sequences and has been successfully used to test for the chronic myeloid leukemia-specific bcr/abl transcripts. We studied blood samples from 17 patients who had undergone allogeneic bone marrow transplantation for CML, using a modi...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Pignon JM,Henni T,Amselem S,Vidaud M,Duquesnoy P,Vernant JP,Kuentz M,Cordonnier C,Rochant H,Goossens M

    更新日期:1990-02-01 00:00:00

  • Insulin-like growth factor 1 is a direct HOXA9 target important for hematopoietic transformation.

    abstract::HOX homeobox proteins are key oncogenic drivers in hematopoietic malignancies. Here we demonstrate that HOXA1, HOXA6 and predominantly HOXA9 are able to induce the production of insulin-like growth factor 1 (Igf1). In chromatin immunoprecipitations, HOXA9 bound directly to the putative promoter and a DNase-hypersensit...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2014.287

    authors: Steger J,Füller E,Garcia-Cuellar MP,Hetzner K,Slany RK

    更新日期:2015-04-01 00:00:00

  • OCT1 and imatinib transport in CML: is it clinically relevant?

    abstract::Imatinib is a highly effective therapy for chronic phase-chronic myeloid leukaemia (CP-CML) patients; however, responses to frontline imatinib are variable. The human organic cation transporter 1 (OCT1; SLC22A1) has been reported to be the main influx transporter involved in imatinib uptake into CML cells. Furthermore...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/leu.2015.170

    authors: Watkins DB,Hughes TP,White DL

    更新日期:2015-10-01 00:00:00

  • Ethnic and geographic diversity of chronic lymphocytic leukaemia.

    abstract::East Asians, Asian Indians and Amerindians have a five to ten-fold lower age-adjusted incidence rate (AAIR) of chronic lymphocytic leukaemia (CLL) compared with persons of predominately European descent. The data we review suggest a genetic rather than environmental basis for this discordance. All these populations ar...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-020-01057-5

    authors: Yang S,Varghese AM,Sood N,Chiattone C,Akinola NO,Huang X,Gale RP

    更新日期:2020-10-19 00:00:00

  • Chromosomal rearrangement on chromosome 11q14-q21 in T cell acute lymphoblastic leukemia.

    abstract::Deletion and translocation involving the bands 11q14 and 11q21 have been detected in five patients with T cell acute lymphoblastic leukemia (ALL). The breakpoint on chromosome 11 was on the same band as that previously described in some acute nonlymphocytic leukemias: monocytic or myelomocytic. The existence of a new ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Berger R,Le Coniat M,Derré J,Vecchione D,Chen SJ

    更新日期:1989-08-01 00:00:00

  • Phase I/II study of 2-chloro-2'-deoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma.

    abstract::Because of their substantial in vitro synergy, we conducted a dose-escalation study of cyclophosphamide (CP) added to 2-chloro-2'-deoxyadenosine (CdA) in patients with previously treated chronic lymphocytic leukemia and non-Hodgkin's lymphoma. CdA was given at a fixed dose (5.6 mg/m2/day) as a 2-h intravenous (i.v.) i...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.leu.2401783

    authors: Van Den Neste E,Louviaux I,Michaux JL,Delannoy A,Michaux L,Sonet A,Bosly A,Doyen C,Mineur P,André M,Straetmans N,Coche E,Venet C,Duprez T,Ferrant A

    更新日期:2000-06-01 00:00:00

  • Clonal instability preceding lymphoid blastic transformation of chronic myeloid leukemia.

    abstract::We have sought the presence of rearrangements of the immunoglobulin heavy chain gene locus in 13 patients with chronic myeloid leukemia (CML) in lymphoid blastic transformation (L-BT) using the polymerase chain reaction (PCR). The lymphoid nature of the transformation was confirmed by immunophenotyping and/or Southern...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400543

    authors: Spencer A,Vulliamy T,Kaeda J,Goldman JM,Melo JV

    更新日期:1997-02-01 00:00:00

  • Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma.

    abstract::This multicentre, open-label phase 1/2 trial determined safety and efficacy of weekly carfilzomib plus cyclophosphamide-dexamethasone (wKCyd) in newly diagnosed multiple myeloma (NDMM) patients aged ⩾65 years or transplant ineligible. Patients received wKCyd for up to nine 28-day cycles, followed by maintenance with c...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究

    doi:10.1038/leu.2017.327

    authors: Bringhen S,D'Agostino M,De Paoli L,Montefusco V,Liberati AM,Galieni P,Grammatico S,Muccio VE,Esma F,De Angelis C,Musto P,Ballanti S,Offidani M,Petrucci MT,Gaidano G,Corradini P,Palumbo A,Sonneveld P,Boccadoro M

    更新日期:2018-04-01 00:00:00

  • Reverse transcription polymerase chain reaction is a reliable assay for detecting leukemic colonies generated by chronic myelogenous leukemia cells.

    abstract::Single-colony karyotyping (SCK) and reverse-transcription polymerase chain reaction (RT-PCR) are two increasingly used techniques for the quantification of leukemic colonies generated by chronic myelogenous leukemia (CML) cell fractions purged or selected in vitro. Recently, the existence of Philadelphia (Ph) chromoso...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400942

    authors: Savoldo B,Sammarelli G,Dotti G,Garau D,Regazzi E,Cilloni D,Tabilio A,Rizzoli V,Carlo-Stella C

    更新日期:1998-03-01 00:00:00

  • CLL family 'Pedigree 14' revisited: 1947-2004.

    abstract::The notion that inherited predisposition contributes to the development of haematological malignancies is generally thought of as being a relatively new idea. However, Videbaek made a clear enunciation of such a hypothesis in 1947, from a study of tumour incidence in relatives of patients with different leukaemias. To...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403727

    authors: Jønsson V,Houlston RS,Catovsky D,Yuille MR,Hilden J,Olsen JH,Fajber M,Brandt B,Sellick G,Allinson R,Wiik A

    更新日期:2005-06-01 00:00:00

  • Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia.

    abstract::Outcomes after unmanipulated haploidentical stem cell transplantation (Haplo) and after unrelated cord blood transplantation (UCBT) are encouraging and have become alternative options to treat patients with high-risk acute leukemia without human leukocyte antigen (HLA) matched donor. We compared outcomes after UCBT an...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2015.98

    authors: Ruggeri A,Labopin M,Sanz G,Piemontese S,Arcese W,Bacigalupo A,Blaise D,Bosi A,Huang H,Karakasis D,Koc Y,Michallet M,Picardi A,Sanz J,Santarone S,Sengelov H,Sierra J,Vincent L,Volt F,Nagler A,Gluckman E,Ciceri F

    更新日期:2015-09-01 00:00:00

  • Treatment by design in leukemia, a meeting report, Philadelphia, Pennsylvania, December 2002.

    abstract::Novel approaches have been designed to treat leukemia based on our understanding of the genetic and biochemical lesions present in different malignancies. This meeting report summarizes some of the recent advances in leukemia treatment. Based on the discoveries of cellular oncogenes, chromosomal translocations, monocl...

    journal_title:Leukemia

    pub_type:

    doi:10.1038/sj.leu.2403156

    authors: Larson RA,Daley GQ,Schiffer CA,Porcu P,Pui CH,Marie JP,Steelman LS,Bertrand FE,McCubrey JA

    更新日期:2003-12-01 00:00:00

  • C3b receptors mediate the growth factor-induced proliferation of malignant B-chronic lymphocytic leukemia lymphocytes.

    abstract::We have investigated the function of C3b receptor (CR1) in the malignant lymphocytes of B-chronic lymphocytic leukemia (B-CLL) mimicking the physiological ligand C3b with the anti-CR1 monoclonal antibody CB04 covalently linked to Sepharose CL-4B (CB04-S). The binding of insolubilized CB04-S to CR1 gave a progression s...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Caligaris-Cappio F,Schena M,Bergui L,Tesio L,Riva M,Rege-Cambrin G,Funaro A,Malavasi F

    更新日期:1987-11-01 00:00:00

  • Homozygous deletions of the CDKN2 (MTS1/p16ink4) gene in cell lines established from children with acute lymphoblastic leukemia.

    abstract::Homozygous deletions of the CDKN2 (MTS1/p16ink4) gene have been found at high frequency in cell lines derived from a variety of adult solid tumors. In order to investigate the status of the CDKN2 gene in cell lines established from childhood acute lymphoblastic leukemia (ALL), we surveyed 25 lines representing the maj...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Zhou M,Gu L,James CD,He J,Yeager AM,Smith SD,Findley HW

    更新日期:1995-07-01 00:00:00

  • Interleukin-6 autoantibodies: possible biological and clinical significance.

    abstract::The pleiotropic cytokines, interleukin (IL)-1 alpha, type I interferons and IL-6 also act on cells involved in antibody production. Somehow the immunologic tolerance to these cytokines is often spontaneously broken--even in healthy individuals. Thus, relatively high concentrations of high affinity IgG antibodies again...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:

    authors: Hansen MB,Svenson M,Diamant M,Abell K,Bendtzen K

    更新日期:1995-07-01 00:00:00

  • Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma.

    abstract::We studied 174 consecutive patients with relapsed refractory multiple myeloma (MM) enrolled on a phase II clinical trial of pomalidomide plus low-dose dexamethasone at Mayo Clinic. Extramedullary disease (EMD) was present at the time of trial entry in 7.5% (13 of 174 patients). The rate of EMD in the first 3 years fol...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2011.29

    authors: Short KD,Rajkumar SV,Larson D,Buadi F,Hayman S,Dispenzieri A,Gertz M,Kumar S,Mikhael J,Roy V,Kyle RA,Lacy MQ

    更新日期:2011-06-01 00:00:00

  • The product of the proto-oncogene c-kit (P145c-kit) is a human bone marrow surface antigen of hemopoietic precursor cells which is expressed on a subset of acute non-lymphoblastic leukemic cells.

    abstract::A monoclonal antibody (17F11) was raised by immunization of a Balb/c mouse with leukemic blasts from a patient with acute non-lymphocytic leukemia (ANLL). This antibody recognizes most leukemic blasts of myeloid but not of lymphoid lineage and no peripheral blood cells. By screening NIH-3T3 fibroblasts transfected wit...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Bühring HJ,Ullrich A,Schaudt K,Müller CA,Busch FW

    更新日期:1991-10-01 00:00:00

  • CAR T-cells targeting FLT3 have potent activity against FLT3-ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib.

    abstract::FMS-like tyrosine kinase 3 (FLT3) is a transmembrane protein expressed on normal hematopoietic stem and progenitor cells (HSC) and retained on malignant blasts in acute myeloid leukemia (AML). We engineered CD8+ and CD4+ T-cells expressing a FLT3-specific chimeric antigen receptor (CAR) and demonstrate they confer pot...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-018-0009-0

    authors: Jetani H,Garcia-Cadenas I,Nerreter T,Thomas S,Rydzek J,Meijide JB,Bonig H,Herr W,Sierra J,Einsele H,Hudecek M

    更新日期:2018-05-01 00:00:00

  • B-cell regulator of immunoglobulin heavy-chain transcription (Bright)/ARID3a is a direct target of the oncomir microRNA-125b in progenitor B-cells.

    abstract::B-cell acute lymphoblastic leukemia (B-ALL) is often associated with chromosomal translocations leading to the deregulation of proto-oncogenes. MicroRNAs can also be affected by chromosomal alterations and thus contribute to carcinogenesis. The microRNA, miR-125b-1, is overexpressed in B-ALL cases with the t(11;14)(q2...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2012.95

    authors: Puissegur MP,Eichner R,Quelen C,Coyaud E,Mari B,Lebrigand K,Broccardo C,Nguyen-Khac F,Bousquet M,Brousset P

    更新日期:2012-10-01 00:00:00

  • Characterization of acute lymphoblastic leukemia of childhood by immunoglobulin and T-cell receptor gene patterns.

    abstract::Molecular biological studies of immunoglobulin (Ig) and T-cell antigen receptor (TCR) genes provide novel approaches to the identification and characterization of the acute lymphoblastic leukemias (ALL). Such studies greatly enhance our understanding of both the cells of origin in these diseases and the order of assem...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:

    authors: Felix CA,Poplack DG

    更新日期:1991-12-01 00:00:00

  • Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia.

    abstract::Genomic analyses of chronic lymphocytic leukemia (CLL) identified somatic mutations and associations of clonal diversity with adverse outcomes. Clonal evolution likely has therapeutic implications but its dynamic is less well studied. We studied clonal composition and prognostic value of seven recurrently mutated driv...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-018-0215-9

    authors: Leeksma AC,Taylor J,Wu B,Gardner JR,He J,Nahas M,Gonen M,Alemayehu WG,Te Raa D,Walther T,Hüllein J,Dietrich S,Claus R,de Boer F,de Heer K,Dubois J,Dampmann M,Dürig J,van Oers MHJ,Geisler CH,Eldering E,Levine RL

    更新日期:2019-02-01 00:00:00

  • Induction treatment of acute promyelocytic leukemia using all-trans retinoic acid. Controversies about dosage, advantages and side-effect management.

    abstract::All-trans retinoic acid (ATRA) in acute promyelocytic leukemia (APL) represents the leading example of targetted drugs for inducing an in vivo differentiation of malignancy (1,2). A fixed dose of 45 mg/m2/day was proposed for the treatment of patients (3), according to the results obtained by retinoic acid derivatives...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章

    doi:

    authors: Dombret H,Castaigne S,Fenaux P,Chomienne C,Degos L

    更新日期:1994-01-01 00:00:00

  • Hematopoietic differentiation of umbilical cord blood-derived very small embryonic/epiblast-like stem cells.

    abstract::A population of CD133(+)Lin(-)CD45(-) very small embryonic/epiblast-like stem cells (VSELs) has been purified by multiparameter sorting from umbilical cord blood (UCB). To speed up isolation of these cells, we employed anti-CD133-conjugated paramagnetic beads followed by staining with Aldefluor to detect aldehyde dehy...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2011.73

    authors: Ratajczak J,Zuba-Surma E,Klich I,Liu R,Wysoczynski M,Greco N,Kucia M,Laughlin MJ,Ratajczak MZ

    更新日期:2011-08-01 00:00:00

  • γδT cells elicited by CMV reactivation after allo-SCT cross-recognize CMV and leukemia.

    abstract::Human cytomegalovirus (CMV) infections and relapse of disease remain major problems after allogeneic stem cell transplantation (allo-SCT), in particular in combination with CMV-negative donors or cordblood transplantations. Recent data suggest a paradoxical association between CMV reactivation after allo-SCT and reduc...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2012.374

    authors: Scheper W,van Dorp S,Kersting S,Pietersma F,Lindemans C,Hol S,Heijhuurs S,Sebestyen Z,Gründer C,Marcu-Malina V,Marchant A,Donner C,Plachter B,Vermijlen D,van Baarle D,Kuball J

    更新日期:2013-06-01 00:00:00

  • Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa.

    abstract::We assessed clinical results in 145 patients with chronic myeloid leukaemia in chronic phase who satisfied criteria for interferon-alpha failure and were thus eligible for treatment with imatinib at the Hammersmith Hospital. We used univariate and multivariate analyses to develop a risk score based on features defined...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402996

    authors: Marin D,Marktel S,Bua M,Szydlo RM,Franceschino A,Nathan I,Foot N,Crawley C,Na Nakorn T,Olavarria E,Lennard A,Neylon A,O'Brien SG,Goldman JM,Apperley JF

    更新日期:2003-08-01 00:00:00

  • Childhood monosomy 7 syndrome: clinical and in vitro studies.

    abstract::The clinical and cell growth characteristics of 11 children with monosomy 7 presenting as preleukemia (eight cases) or acute nonlymphoblastic leukemia (three cases) were studied. Anemia was common to all patients, with nine showing leukocytosis, seven thrombocytopenia, and one thrombocytosis. There was a striking pred...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Weiss K,Stass S,Williams D,Kalwinsky D,Dahl GV,Wang W,Johnson FL,Murphy SB,Dow LW

    更新日期:1987-02-01 00:00:00

  • Dissecting the pathways to death.

    abstract::This report summarizes recent findings in the field of basic and translational apoptosis research which were presented at the 1st Conference on 'Mechanisms of Cell Death and Disease: Advances in Therapeutic Intervention' organized by the European School of Hematology and the University of Texas MD Anderson Cancer Cent...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/sj.leu.2401940

    authors: Daniel PT

    更新日期:2000-12-01 00:00:00

  • BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells.

    abstract::Myeloproliferative neoplasms with myelofibrosis (MPN-MF) demonstrate constitutive activation of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling that responds to treatment with the JAK1 and 2 kinase inhibitor (JAKi) ruxolitinib. However, MPN-MF often progresses (~20%) to secondary acu...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2016.260

    authors: Saenz DT,Fiskus W,Manshouri T,Rajapakshe K,Krieger S,Sun B,Mill CP,DiNardo C,Pemmaraju N,Kadia T,Parmar S,Sharma S,Coarfa C,Qiu P,Verstovsek S,Bhalla KN

    更新日期:2017-03-01 00:00:00

  • Evaluation of the impact of allogenic transplant in first remission on an unselected population of patients with acute myeloid leukaemia aged 15-55 years. The Northern Regional Haematology Group.

    abstract::The aim of this study was to collect prospectively unselected, population-based data on young adults with acute myeloid leukaemia (AML) over a 9-year period and to evaluate the impact on survival of the introduction of allogeneic transplantation performed in first remission. The population within the Northern Region o...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章

    doi:

    authors: Proctor SJ,Taylor PR,Stark A,Carey PJ,Bown N,Hamilton PJ,Reid MM

    更新日期:1995-07-01 00:00:00